loading
Precedente Chiudi:
$2.55
Aprire:
$2.55
Volume 24 ore:
191.45K
Relative Volume:
0.94
Capitalizzazione di mercato:
$74.35M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-1.8923
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
+13.33%
1M Prestazione:
+27.50%
6M Prestazione:
-14.72%
1 anno Prestazione:
-34.95%
Intervallo 1D:
Value
$2.50
$2.5891
Intervallo di 1 settimana:
Value
$2.27
$2.6732
Portata 52W:
Value
$1.90
$4.01

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
Nome
Vistagen Therapeutics Inc
Name
Telefono
650-577-3600
Name
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
57
Name
Cinguettio
@vistagen
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.55 69.40M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.90 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
556.16 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
574.71 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.14 27.29B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-07 Aggiornamento Jefferies Hold → Buy
2023-08-07 Aggiornamento Maxim Group Hold → Buy
2022-07-22 Downgrade Jefferies Buy → Hold
2022-07-22 Downgrade Robert W. Baird Outperform → Neutral
2022-07-22 Downgrade William Blair Outperform → Mkt Perform
2021-05-20 Iniziato Robert W. Baird Outperform
2021-02-18 Iniziato Jefferies Buy
2021-01-04 Aggiornamento William Blair Mkt Perform → Outperform
2018-06-27 Iniziato Maxim Group Buy
2018-02-08 Reiterato Chardan Capital Markets Buy
2017-03-28 Iniziato Maxim Group Buy
Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

pulisher
08:24 AM

Vistagen Therapeutics Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com

08:24 AM
pulisher
Jul 21, 2025

What analysts say about Vistagen Therapeutics Inc. stockAccelerated investment success - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Is Vistagen Therapeutics Inc. a good long term investmentHigh-velocity capital appreciation - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat

Jul 19, 2025
pulisher
Jul 19, 2025

What drives Vistagen Therapeutics Inc. stock priceRapid wealth accumulation - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Vistagen Therapeutics Inc. stock price move sharplyFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan

Jul 15, 2025
pulisher
Jul 13, 2025

Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com

Jul 13, 2025
pulisher
Jul 11, 2025

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN

Jul 11, 2025
pulisher
Jun 26, 2025

Research Analysts Set Expectations for VTGN Q1 Earnings - MarketBeat

Jun 26, 2025
pulisher
Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 25, 2025

Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com

Jun 25, 2025
pulisher
Jun 23, 2025

William Blair Issues Negative Forecast for VTGN Earnings - Defense World

Jun 23, 2025
pulisher
Jun 22, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Jun 22, 2025
pulisher
Jun 21, 2025

William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat

Jun 21, 2025
pulisher
Jun 20, 2025

Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest

Jun 20, 2025
pulisher
Jun 19, 2025

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Jun 19, 2025
pulisher
Jun 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise

Jun 17, 2025
pulisher
Jun 17, 2025

Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen to Report Fiscal Year 2025 Financial Results and Host C - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus

Jun 16, 2025

Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.80
price up icon 0.50%
$35.90
price up icon 0.67%
$103.38
price up icon 0.60%
$26.43
price up icon 0.30%
$109.96
price up icon 0.27%
biotechnology ONC
$294.50
price up icon 0.88%
Capitalizzazione:     |  Volume (24 ore):